Blood cancer

#American Society of Hematology #Blood cancer #Cancer research #CAR-T #Haematology #Oncology

This week in drug discovery (11-15 December) 

News round-up for 11-15 December by DDW Digital Content Editor Diana Spencer. Our news highlights this week focus on haematology, thanks in part to a number of key announcements at the 65th American Society for Hematology meeting (ASH) Annual Meeting, including real-world evidence on the use of… Read More

#News

Myeloma cells
#Blood cancer #CellCentric #Haematology #Myeloma #Oncology #Phase I trial

New class of drug shows promise in last line multiple myeloma

Data presented at the American Society for Hematology meeting (ASH) show a 70% response rate in last line multiple myeloma patients treated with CellCentric’s inobrodib in combination with pomalidomide (pom) and dexamethasone (dex). Inobrodib is the first in a new class of drug, which disrupts the… Read More

#Cancer Research #News

Blood cancer
#Acute Myeloid Leukaemia #Biologics #Blood cancer #CAR-T #University College London #ViroCell Biologics

UCL accelerates research of relapse in childhood blood cancer 

The University College London (UCL) has entered into a partnership with ViroCell Biologics to advance Professor Persis Amrolia’s innovative chimeric antigen receptor (CAR) T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia (ALL).   Dr Amrolia is Professor of Transplantation Immunology at the UCL Great Ormond Street Institute of… Read More

#Cancer Research #News

CAR-T therapy
#Blood cancer #CAR-T #Haematology #Kite Pharma #Oncology #Real world data

Real-world evidence supports use of CAR-T therapies in blood cancers

Real-world evidence from the French DESCAR-T registry has shown an overall response rate (ORR) of 76.9% and complete response rate (CR) of 57.7% in large B-cell lymphoma (LBCL) patients treated with axicabtagene ciloleucel (Yescarta). Axicabtagene ciloleucel was also associated with less than 5% grade ≥3 cytokine… Read More

#Cancer Research #News #Trending News

Acute lymphoblastic leukemia
#Blood cancer #Eli Lilly #FDA #Leukaemia #Oncology

FDA approves second indication for Lilly’s BTK inhibitor Jaypirca

Eli Lilly’s Jaypirca (pirtobrutinib) has been approved in the US for lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL). It has been granted approval by the Food and Drug Administration (FDA) to treat patients who have received at least two lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor and… Read More

#News #Regulatory

FDA headquarters
#Adverse event #Blood cancer #CAR-T #Cell therapy #FDA #Immunotherapy #Oncology

FDA investigates safety of CAR-T cell immunotherapies

The Food and Drug Administration (FDA) said it will investigate the safety of BCMA- or CD19-directed autologous CAR-T cell immunotherapies, following reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in these patients. The reports were received from clinical trials and postmarketing adverse event (AE) data sources. Despite… Read More

#News #Regulatory #Trending News

Blood cells
#Blood cancer #Bristol Myers Squibb #FDA #Oncology #Phase III trial

FDA expands Reblozyl approval to first-line use

The US Food and Drug Administration (FDA) has expanded the use of Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) to include first-line treatment of anaemia in adults with lower-risk myelodysplastic syndromes (MDS). The approval is for the treatment of anaemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low-… Read More

#News #Regulatory

Leukaemia
#Blood cancer #Cancer research #CHMP #EMA #European Commission #Jazz Pharmaceuticals #Leukaemia #Oncology

EU positive opinion for acute lymphoblastic leukaemia drug

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorisation of JZP458 (a recombinant Erwinia asparaginase or crisantaspase). It has been recommended for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic… Read More

#News #Regulatory

CAR-T therapy
#Blood cancer #CAR-T #Cell therapy #Gilead Sciences #Kite Pharma #National Institute for Health and Care Excellence (NICE) #Oncology

UK’s NICE expands use of CAR-T cell therapy for blood cancer

The UK’s National Institute for Health and Care Excellence (NICE) has recommended additional uses for two CAR-T therapies from Gilead Sciences/Kite, as part of the Cancer Drugs Fund (CDF). Yescarta (axicabtagene ciloleucel: axi-cel) has been recommended by NICE for the treatment of eligible adult patients with diffuse large B cell… Read More

#News #Regulatory #Trending News

Leukaemia
#AACR 2023 #Blood cancer #Cancer research #Human disease models #Oncology

Unique new models will empower leukaemia research

Tisch Cancer Center scientists have developed unique models of acute myeloid leukaemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance. The research was presented at the annual meeting of the American Association of Cancer Research and simultaneously… Read More

#Cancer Research #News

Bone marrow organoids
#Blood cancer #Cancer research #Personalised medicine

‘Bone marrow in a dish’ used to study personalised cancer drugs

Scientists from Oxford University and the University of Birmingham have made the first bone marrow ‘organoids’ that include all the key components of human marrow.   The technology allows for the screening of multiple anti-cancer drugs at the same time, as well as testing personalised treatments for individual… Read More

#Cancer Research #News

#Acute Myeloid Leukaemia #Blood cancer #Cancer research #Investment #Leukaemia #Plecoid

Pleco Therapeutics raises €17.3m to progress leukaemia drug

Pleco Therapeutics BV has raised €17.3 million in its Series A financing round, which will be used to complete the development of its Plecoid Product, PTX-061, to improve the effectiveness of chemotherapy in patients with acute myeloid leukaemia (AML). The investments include €3.6 million committed by Oost NL and a… Read More

#News

#Assays #Blood cancer #Cancer research

SAGA Diagnostics and AstraZeneca enter assay development agreement

SAGA Diagnostics, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with Astra Zeneca to develop SAGAsafe dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies.   James Hadfield,… Read More

#News

#Blood cancer #Cancer research #Collaboration #Oncology

New cancer ‘inhibitor’ could lead to improved treatment options

Researchers have discovered a potential advancement in the treatment of chronic myeloid leukaemia (CML), which they hope will one day offer an improved option for treating patients with this form of blood cancer. The study– published in Science Translational Medicine and led by the University of Glasgow in collaboration with… Read More

#Cancer Research #Editor's Choice #News #Trending News